Novakand Pharma AB (FRA:3EE0) ROCE %: -115.03% (As of Dec. 2025)


What is Novakand Pharma AB ROCE %?

Novakand Pharma AB FRA:3EE0 ROCE % is -115.03% as of Dec. 2025. The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Novakand Pharma AB's annualized ROCE % for the quarter that ended in Dec. 2025 was -115.03%.

Novakand Pharma AB  (FRA:3EE0) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Novakand Pharma AB ROCE % Related Terms

Novakand Pharma AB ROCE % Historical Data

* Premium members only.

The historical data trend for Novakand Pharma AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novakand Pharma AB ROCE % Chart

Novakand Pharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -46.38 -43.90 -83.88 -82.94 -79.96

Novakand Pharma AB Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -58.61 -96.42 -54.71 -65.13 -115.03

Novakand Pharma AB ROCE % Calculation

Novakand Pharma AB's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-2.719/( ( (5.817 - 0.401) + (1.538 - 0.153) )/ 2 )
=-2.719/( (5.416+1.385)/ 2 )
=-2.719/3.4005
=-79.96 %

Novakand Pharma AB's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=-1.844/( ( (2.108 - 0.287) + (1.538 - 0.153) )/ 2 )
=-1.844/( ( 1.821 + 1.385 )/ 2 )
=-1.844/1.603
=-115.03 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -115.03% mean?
Novakand Pharma AB (FRA:3EE0) has a ROCE % of -115.03% as of Dec. 2025.
Is Novakand Pharma AB's ROCE % too high?
Novakand Pharma AB's current ROCE % is -115.03%.
How does Novakand Pharma AB's ROCE % compare to VRTX and REGN?
Novakand Pharma AB's ROCE % of -115.03% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Novakand Pharma AB's current ROCE % is -115.03%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novakand Pharma AB stock overvalued right now?
Novakand Pharma AB (FRA:3EE0) has a current ROCE % of -115.03%. The current ROCE % is -115.03%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Novakand Pharma AB (FRA:3EE0), the current ROCE % is -115.03% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Novakand Pharma AB Business Description

Address Nanna Svarts vag 4, Solna, SWE, 171 65
Novakand Pharma AB is developing a new class of innovative drugs focusing on inflammatory diseases and cancer. The company is developing a new class of small molecule drugs that control disease promoting immune cells with precision, by targeting the fractalkine axis.